These data suggest that MDM2 inhibitors might also have a pronounced anti-tumor effect in tumor cells carrying inactivating p53 mutations by reactivating p73 and could successfully function in therapeutic approaches involving personalized treatment for p53-mutated TNBC. This evidence concerns the gene MDM2 and neoplasm.